This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube Usage

This study has been completed.
Information provided by:
Nanovibronix Identifier:
First received: October 26, 2008
Last updated: March 24, 2009
Last verified: March 2009
The purpose of the study i to demonstrate the safety and efficacy of a device that intends to reduce pain/discomfort related to nasogfastric tube usage by reducing the friction between the tube and internal orifice (nose and pharynx)using micro vibrations

Condition Intervention Phase
Intubation, Nasogastric Device: NG Shield Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Supportive Care
Official Title: Evaluation of Safety and Efficacy of the NasoGastric Shield (NG Shield) in Healthy Subjects With Indwelling Nasogastric Tube

Further study details as provided by Nanovibronix:

Primary Outcome Measures:
  • Pain/discomfort levelusing flicker scale (1-10 scale)during indwelling phase [ Time Frame: every 30 minutes for 6 hours ]
  • safety of device usage [ Time Frame: 6 hours ]

Secondary Outcome Measures:
  • pain/Dicomfort during insertion and removal of the nasogastric tube [ Time Frame: at t=0h and t=6h ]

Estimated Enrollment: 24
Study Start Date: September 2008
Study Completion Date: December 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
starting with active NG Shield
Device: NG Shield
A device to reduce pain/discomfort related to nasogastric tube usage
Experimental: 2
Starting with inactive NG Shield
Device: NG Shield
A device to reduce pain/discomfort related to nasogastric tube usage


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Subject is in good health and able to undergoes the NG tube insertion procedure, according to the PI decision
  2. Subject is able to understand and answer the pain and discomfort questionnaires
  3. Subject has been fasting for at least 12h prior to the insertion phase
  4. Subject underwent a physical examination by the PI
  5. Subject able, agrees and signs the Inform Consent Form (ICF)

Exclusion Criteria:

  1. Subject has any history of dysphagia or esophageal disease
  2. Subject used anti pain medications during the last week prior to the study date
  3. Subject used Antibiotics during the last week prior to the study date
  4. Subject with Asthma
  5. Subject with chronic or acute nasal or throat disorder
  6. Subject who suffered from upper respiratory infection at least 7 days prior to the insertion procedure
  7. Any pain from other source prior to the initiation of the study procedure according to the PI judgment and decision
  8. Subject has any condition, which precludes compliance with study and/or device instruction for use
  9. Subject is currently participating in another clinical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00781248

"Bikur Cholim" Hospital
Jerusalem, Israel
Sponsors and Collaborators
Principal Investigator: Shmuel Adler, M.D "Bikur Cholim" Hospital, Jerusalem ISRAEL
  More Information

Responsible Party: Dr. Dagan Harris VP Clinical Affairs, NanoVibronix Identifier: NCT00781248     History of Changes
Other Study ID Numbers: NV-NGS-06-001
Study First Received: October 26, 2008
Last Updated: March 24, 2009

Keywords provided by Nanovibronix:
enteral feeding
Subject who requires nasogastric tube processed this record on August 17, 2017